JP2006519028A5 - - Google Patents

Download PDF

Info

Publication number
JP2006519028A5
JP2006519028A5 JP2006508841A JP2006508841A JP2006519028A5 JP 2006519028 A5 JP2006519028 A5 JP 2006519028A5 JP 2006508841 A JP2006508841 A JP 2006508841A JP 2006508841 A JP2006508841 A JP 2006508841A JP 2006519028 A5 JP2006519028 A5 JP 2006519028A5
Authority
JP
Japan
Prior art keywords
influenza virus
composition
influenza
egg
live
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006508841A
Other languages
English (en)
Japanese (ja)
Other versions
JP4617300B2 (ja
JP2006519028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/005697 external-priority patent/WO2005014862A1/en
Publication of JP2006519028A publication Critical patent/JP2006519028A/ja
Publication of JP2006519028A5 publication Critical patent/JP2006519028A5/ja
Application granted granted Critical
Publication of JP4617300B2 publication Critical patent/JP4617300B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006508841A 2003-02-25 2004-02-25 インフルエンザワクチン組成物を生成する方法 Expired - Fee Related JP4617300B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45018103P 2003-02-25 2003-02-25
PCT/US2004/005697 WO2005014862A1 (en) 2003-02-25 2004-02-25 Methods of producing inflenza vaccine compositions

Publications (3)

Publication Number Publication Date
JP2006519028A JP2006519028A (ja) 2006-08-24
JP2006519028A5 true JP2006519028A5 (https=) 2007-04-12
JP4617300B2 JP4617300B2 (ja) 2011-01-19

Family

ID=34135009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006508841A Expired - Fee Related JP4617300B2 (ja) 2003-02-25 2004-02-25 インフルエンザワクチン組成物を生成する方法

Country Status (8)

Country Link
US (5) US7262045B2 (https=)
EP (2) EP2481819A1 (https=)
JP (1) JP4617300B2 (https=)
KR (4) KR101190932B1 (https=)
CN (2) CN100582244C (https=)
AU (2) AU2004263813B8 (https=)
CA (2) CA2517181C (https=)
WO (1) WO2005014862A1 (https=)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CA2491145A1 (en) * 2002-07-03 2004-01-15 Basf Aktiengesellschaft Microorganisms and processes for enhanced production of pantothenate
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
SG150501A1 (en) * 2004-02-05 2009-03-30 Millipore Corp Porous adsorptive or chromatographic media
EP2769735B1 (en) * 2004-10-06 2017-04-19 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
DK1869471T3 (en) * 2005-04-13 2016-08-01 Merial Inc PROCEDURE FOR MANUFACTURING PIG CIRCOVIRUS
US20060275170A1 (en) * 2005-06-02 2006-12-07 Mahmoud Ameri Method for terminal sterilization of transdermal delivery devices
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP1917352A4 (en) * 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US7534596B2 (en) * 2006-02-10 2009-05-19 Solohill Engineering, Inc. Method and device for producing vaccine
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2615167A1 (en) 2006-09-15 2013-07-17 MedImmune, LLC Method for eliminating DNA contaminants from viral preparations
JP2010512748A (ja) * 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
AU2008225501B2 (en) * 2007-03-09 2013-08-29 Otsuka Pharmaceutical Co., Ltd. Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
EP2674486A1 (en) * 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
CA2705461A1 (en) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
JP2011184299A (ja) * 2008-07-02 2011-09-22 Asahi Kasei Medical Co Ltd モノクローナル抗体を含む製剤の製造方法
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
EP2344634A4 (en) 2008-09-24 2012-08-29 Medimmune Llc METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES
CN102223895B (zh) * 2008-11-25 2014-11-05 巴克斯特保健股份有限公司 生产pH稳定的包膜病毒的方法
CN107365751B (zh) 2008-12-16 2021-07-09 纳米医疗公司 流感疫苗的生产
CN101450209B (zh) * 2008-12-31 2012-01-25 中国人民解放军军事医学科学院微生物流行病研究所 透皮免疫流感多价疫苗的制备及其方法
RU2424762C2 (ru) * 2009-05-06 2011-07-27 Валерий Денисович Белокрылов Способ и автоматизированное устройство (два варианта) для диагностики заболеваний, вызванных вирусом a/h1n1 и его мутациями
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US20120077249A1 (en) * 2010-04-20 2012-03-29 Millipore Corporation Separation Of Virus And/Or Protein From Nucleic Acids By Primary Amines
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103282873B (zh) * 2010-11-12 2016-08-24 生命科技公司 用于实验室测定确认或验证的系统和方法
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2012136852A1 (en) 2011-04-08 2012-10-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for increasing the replication capacity of an influenza virus in cultured cells
EP2710381A2 (en) 2011-05-16 2014-03-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for screening substances capable of modulating the replication of an influenza virus
CN103827296B (zh) * 2011-07-20 2016-11-16 雅培生物学有限责任公司 用于产生病毒抗原和疫苗的方法
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
US9932620B2 (en) 2012-05-21 2018-04-03 Celsis Ltd. Methods, devices, and systems of detecting microorganisms
US20130309700A1 (en) * 2012-05-21 2013-11-21 Celsis International Limited Methods, devices, and systems of detecting microorganisms
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2014142433A1 (ko) 2013-03-13 2014-09-18 고려대학교산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
WO2015017673A1 (en) * 2013-08-01 2015-02-05 Medimmune, Llc Methods for producing influenza vaccine compositions
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
JP6550072B2 (ja) * 2014-04-03 2019-07-24 バイオンドバックス ファーマシューティカルズ リミテッド 多量体マルチエピトープインフルエンザポリペプチドの組成物及びそれらの生成
WO2015194770A1 (ko) 2014-06-18 2015-12-23 고려대학교산학협력단 Bst2 유전자의 기능이 상실된 세포주를 이용한 바이러스 감염 촉진 및 생산 증진 방법
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
EP4523756A3 (en) 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3381468A4 (en) * 2015-11-27 2019-06-05 Nitto Denko Corporation DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING A DRIED INFLUENZED VACCINE PREPARATION
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
US20220056481A1 (en) 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
BR112021016059A2 (pt) * 2019-02-15 2021-10-13 Serum Institute Of India Pvt Ltd. Composição de vacina de vírus de influenza atenuada viva e processo para a preparação da mesma
JP7712284B2 (ja) * 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
KR20260001978A (ko) 2024-06-28 2026-01-06 주식회사 엔에프방재 화재 방재용 방패

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB660109A (en) * 1946-10-01 1951-10-31 American Cyanamid Co Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US3874999A (en) * 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
US4000257A (en) * 1975-12-22 1976-12-28 American Cyanamid Company Process for the purification of influenza virus vaccine
US4057626A (en) 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
US4338296A (en) * 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4512972A (en) * 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4512285A (en) * 1983-12-27 1985-04-23 Gof Manufacturing Company, Inc. Apparatus and method for egg turning during incubation
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
DE69032102T2 (de) * 1989-08-15 1998-06-25 Massachusetts Inst Technology Stabilisierte impfstoffzusammensetzungen
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
ATE213646T1 (de) 1995-10-20 2002-03-15 Yissum Res Dev Co Grippe-impfstoff
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6177082B1 (en) * 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
NZ512980A (en) 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
RU2002112751A (ru) * 1999-11-12 2004-02-27 Файброджен, Инк. (Us) Рекомбинантные желатины
CN1147316C (zh) * 2000-03-16 2004-04-28 辽宁天成生物制药研究所 流感病毒静水压技术灭活工艺制备疫苗的方法
ES2319864T3 (es) 2000-04-28 2009-05-14 St. Jude Children's Research Hospital Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.
BRPI0002694C1 (pt) 2000-06-19 2021-05-25 Fund Butantan processo de obtenção de vacina contra raiva em células vero, para uso humano
JP5063852B2 (ja) 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 生ワクチン及び製造方法
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
WO2003087335A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2003087327A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
HUE025727T2 (en) 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
EP2769735B1 (en) 2004-10-06 2017-04-19 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions

Similar Documents

Publication Publication Date Title
JP2006519028A5 (https=)
WO2005014862B1 (en) Methods of producing inflenza vaccine compositions
Kumar et al. Virological and immunological outcomes of coinfections
Almansour Mumps vaccines: current challenges and future prospects
Fu et al. Emergence of a new GII. 17 norovirus variant in patients with acute gastroenteritis in Jiangsu, China, September 2014 to March 2015
Chan et al. Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study
Hanley et al. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes
Hannoun The evolving history of influenza viruses and influenza vaccines
Schmidt et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone
Colas de la Noue et al. Absolute humidity influences the seasonal persistence and infectivity of human norovirus
Hosseini et al. Molecular characterization and phylogenetic study of Newcastle disease viruses isolated in Iran, 2010–2012
Wen et al. Molecular basis for the thermostability of Newcastle disease virus
JP2009034115A5 (https=)
Yadav et al. Characterization of novel reoviruses wad medani virus (orbivirus) and kundal virus (coltivirus) collected from hyalomma anatolicum ticks in india during surveillance for crimean congo hemorrhagic fever
CN105517568B (zh) 防止病毒组分聚集的方法
Ábrego et al. Genetic variability of human respiratory syncytial virus group B in Panama reveals a novel genotype BA14
Takeuchi et al. Wild-type measles virus with the hemagglutinin protein of the Edmonston vaccine strain retains wild-type tropism in macaques
Emara et al. Mutation of mapped TIA-1/TIAR binding sites in the 3′ terminal stem-loop of West Nile virus minus-strand RNA in an infectious clone negatively affects genomic RNA amplification
Silva et al. Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturing
Takeuchi et al. Recombinant wild-type and Edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificity
Sreenivasan et al. Influenza C and D viruses demonstrated a differential respiratory tissue tropism in a comparative pathogenesis study in guinea pigs
Bartlett et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys
Escoffier et al. Infection of chicken embryonic fibroblasts by measles virus: adaptation at the virus entry level
Joseph et al. Adaptive evolution during the establishment of European avian‐like H 1 N 1 influenza A virus in swine
Bennett et al. Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes